Advertisement
BIO vs TMO
Which Stock Would AI Choose? Bio-Rad Laboratories (BIO) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- BIO and TMO operate in the life sciences and diagnostics sector, with TMO representing a significantly larger scale in instruments, reagents, and services.
- Recent market activity shows TMO preparing for second-quarter 2026 earnings on July 23, following a first-quarter revenue increase of 6% to $11.01 billion.
- BIO maintains a focused portfolio in clinical diagnostics and life science research products, offering exposure to specialized laboratory applications.
- Sector sentiment has been influenced by demand trends in healthcare and research funding, with both stocks reflecting broader life sciences positioning.
- Relative performance highlights trade-offs between TMO's diversified global reach and BIO's more concentrated business model.
- Market positioning suggests investors may weigh stability from larger capitalization against niche opportunities in smaller peers.
Introduction
This comparison examines BIO (Bio-Rad Laboratories) and TMO (Thermo Fisher Scientific), two companies serving scientific research, diagnostics, and laboratory markets. The analysis focuses on their business models, recent performance trends, and market positioning within the life sciences sector. Traders and investors monitoring healthcare and biotechnology exposure, as well as those evaluating relative value in equipment and consumables providers, may find this overview relevant for understanding sector dynamics and company-specific factors in the current environment.
BIO Overview and Recent Performance
Bio-Rad Laboratories develops and manufactures products for clinical diagnostics and life science research, including reagents, instruments, and quality control solutions used in laboratories worldwide. In recent weeks, the stock has reflected broader sector movements amid fluctuating demand for research tools and diagnostic testing. Market activity has been shaped by ongoing trends in academic and pharmaceutical research spending, with sentiment influenced by macroeconomic factors affecting laboratory budgets. Performance has shown typical volatility associated with smaller-capitalization names in the space, as investors assess supply chain stability and product adoption rates.
TMO Overview and Recent Performance
Thermo Fisher Scientific provides a wide array of analytical instruments, reagents, consumables, and services to support life science research, diagnostics, and applied markets. Recent market activity includes preparation for second-quarter 2026 earnings, scheduled for release on July 23, with analyst expectations centered on revenue around $11.68 billion and EPS of $5.71. Following first-quarter results that showed 6% revenue growth to $11.01 billion, the stock has experienced price fluctuations consistent with healthcare sector movements. Sentiment has been affected by commentary on demand recovery in academic and government segments, alongside global economic considerations.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of AI trading bots from hundreds available across thousands of tickers. Only those demonstrating strong alignment with prevailing market conditions earn placement in this section. Available bots feature varied trading styles, strategies, timeframes, performance metrics, and ticker sets, with statistics often including win rates, drawdowns, and return ranges that differ significantly by bot. This diversity allows users to explore options suited to different risk tolerances and market views. For additional details on current trending selections, visit Trending AI Robots.
Head-to-Head Comparison
BIO and TMO both serve life sciences customers but differ substantially in scale and scope. TMO offers broader diversification across instruments, consumables, and contract services with global operations, while BIO concentrates on specialized reagents and diagnostic tools. Growth drivers for TMO include recurring revenue streams and M&A (mergers and acquisitions) integration, contrasted with BIO’s emphasis on product innovation in niche laboratory applications. Recent momentum has favored larger peers amid earnings visibility, though both face sector risks such as funding variability and regulatory changes. Market sentiment reflects TMO’s established position versus BIO’s potential for targeted upside in specific research segments.
Tickeron AI Verdict
Based on observable factors including trend consistency, earnings visibility, and relative market positioning, Tickeron’s AI models would currently assign a higher probabilistic preference to TMO. The larger company’s scale, upcoming earnings catalyst, and diversified exposure provide a more stable profile in recent market conditions compared to the narrower focus of BIO. This assessment remains probabilistic and tied to prevailing data rather than forward guarantees.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsTo compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a Buy and TMO is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 1 FA rating(s) are green whileTMO’s FA Score has 2 green FA rating(s).
- BIO’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 5 TA indicator(s) are bullish while TMO’s TA Score has 5 bullish TA indicator(s).
- BIO’s TA Score: 5 bullish, 3 bearish.
- TMO’s TA Score: 5 bullish, 5 bearish.
Price Growth
BIO (@Medical/Nursing Services) experienced а +1.13% price change this week, while TMO (@Medical Specialties) price change was -1.99% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -4.61%. For the same industry, the average monthly price growth was -3.67%, and the average quarterly price growth was -20.44%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.48%. For the same industry, the average monthly price growth was +8.99%, and the average quarterly price growth was +0.10%.
Reported Earning Dates
BIO is expected to report earnings on Jul 30, 2026.
TMO is expected to report earnings on Jul 23, 2026.
Industries' Descriptions
@Medical/Nursing Services (-4.61% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+0.48% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BIO | TMO | BIO / TMO | |
| Capitalization | 8.11B | 195B | 4% |
| EBITDA | 440M | 11.7B | 4% |
| Gain YTD | -0.426 | -9.483 | 4% |
| P/E Ratio | 50.20 | 28.78 | 174% |
| Revenue | 2.59B | 45.2B | 6% |
| Total Cash | 1.57B | 1.12B | 140% |
| Total Debt | 1.38B | 43.2B | 3% |
BIO | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 57 | 31 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 90 | |
SMR RATING 1..100 | 90 | 62 | |
PRICE GROWTH RATING 1..100 | 49 | 48 | |
P/E GROWTH RATING 1..100 | 10 | 31 | |
SEASONALITY SCORE 1..100 | 85 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (13) in the Medical Specialties industry is significantly better than the same rating for BIO (85). This means that TMO’s stock grew significantly faster than BIO’s over the last 12 months.
TMO's Profit vs Risk Rating (90) in the Medical Specialties industry is in the same range as BIO (100). This means that TMO’s stock grew similarly to BIO’s over the last 12 months.
TMO's SMR Rating (62) in the Medical Specialties industry is in the same range as BIO (90). This means that TMO’s stock grew similarly to BIO’s over the last 12 months.
TMO's Price Growth Rating (48) in the Medical Specialties industry is in the same range as BIO (49). This means that TMO’s stock grew similarly to BIO’s over the last 12 months.
BIO's P/E Growth Rating (10) in the Medical Specialties industry is in the same range as TMO (31). This means that BIO’s stock grew similarly to TMO’s over the last 12 months.
| BIO | TMO | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 54% |
| Stochastic ODDS (%) | 1 day ago 74% | 1 day ago 57% |
| Momentum ODDS (%) | 1 day ago 71% | 1 day ago 64% |
| MACD ODDS (%) | 1 day ago 69% | 1 day ago 57% |
| TrendWeek ODDS (%) | 1 day ago 66% | 1 day ago 60% |
| TrendMonth ODDS (%) | 1 day ago 66% | 1 day ago 61% |
| Advances ODDS (%) | 6 days ago 66% | 7 days ago 61% |
| Declines ODDS (%) | 1 day ago 69% | 1 day ago 63% |
| BollingerBands ODDS (%) | 1 day ago 68% | 1 day ago 59% |
| Aroon ODDS (%) | 1 day ago 74% | 1 day ago 59% |
Advertisement